{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:03:58Z","timestamp":1779915838754,"version":"3.53.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jfma.2026.04.068","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:01:39Z","timestamp":1779912099000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u201cDaratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study\u201d"],"prefix":"10.1016","author":[{"given":"Shobana","family":"Chandrasekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Rohith Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2026.04.068_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2026.03.120","article-title":"Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: a real-world propensity score-matched study","author":"Lin","year":"2026","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2026.04.068_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-14087-y","article-title":"Lenalidomide based triplets in relapsed\/refractory multiple myeloma: analysis of the Czech myeloma group","author":"Minarik","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jfma.2026.04.068_bib3","author":"Konigorski"},{"key":"10.1016\/j.jfma.2026.04.068_bib4","author":"Farrell"},{"key":"10.1016\/j.jfma.2026.04.068_bib5","article-title":"Long-term outcomes in Waldenstr\u00f6m macroglobulinemia (WM) patients who discontinue bruton tyrosine kinase inhibitor (BTKi) therapy","author":"Chohan","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626004079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626004079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:01:40Z","timestamp":1779912100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626004079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":5,"alternative-id":["S0929664626004079"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.04.068","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on \u201cDaratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.04.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}